|
Supplementary Protection Certificate (SPC) Summary of Applications |
|||
| SPC No. | 2023/002 | ||
|---|---|---|---|
| Date of filing | 25/01/2023 | ||
| Notification of Application Published | |||
| Status | Pending | ||
| Notification of Grant Published | |||
| Date of Expiry of SPC | |||
| Applicant |
ELI LILLY AND COMPANY Lilly Corporate Center Indianapolis, IN 46285 UNITED STATES OF AMERICA |
||
| Patent Number | 3242887 | ||
| Title of Invention | GIP AND GLP-1 CO-AGONIST COMPOUNDS | ||
| Date of Expiry of Patent | 04/01/2036 | ||
| Product Type | Medicinal Product | ||
| Product Identity | tirzepatide and pharmaceutically acceptable salts thereof | Market Authorisation | Ireland | European Union |
| Authorisation No | EU/1/22/1685 | EU/1/22/1685 | |
| Authorisation Date | 19/09/2022 | 19/09/2022 | |
| Identity of Product Authorised | Mounjaro - tirzepatide | Mounjaro - tirzepatide | |
| Address for Service |
FRKelly Waterways House Grand Canal Quay Dublin D02 PD39 IRELAND |
||
| Renewal Fees | |||
| 26/01/2023 | Request for grant a Supplementary Protection Certificate filed on 25/01/2023, numbered 2023/002. | ||